JP2021091728A5 - - Google Patents

Download PDF

Info

Publication number
JP2021091728A5
JP2021091728A5 JP2021036502A JP2021036502A JP2021091728A5 JP 2021091728 A5 JP2021091728 A5 JP 2021091728A5 JP 2021036502 A JP2021036502 A JP 2021036502A JP 2021036502 A JP2021036502 A JP 2021036502A JP 2021091728 A5 JP2021091728 A5 JP 2021091728A5
Authority
JP
Japan
Prior art keywords
ala
group
peptides
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021036502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021091728A (ja
JP7184946B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021091728A publication Critical patent/JP2021091728A/ja
Publication of JP2021091728A5 publication Critical patent/JP2021091728A5/ja
Priority to JP2022187561A priority Critical patent/JP2023010979A/ja
Application granted granted Critical
Publication of JP7184946B2 publication Critical patent/JP7184946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021036502A 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 Active JP7184946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022187561A JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017516948A Division JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022187561A Division JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Publications (3)

Publication Number Publication Date
JP2021091728A JP2021091728A (ja) 2021-06-17
JP2021091728A5 true JP2021091728A5 (https=) 2021-09-30
JP7184946B2 JP7184946B2 (ja) 2022-12-06

Family

ID=55582262

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017516948A Active JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017516948A Active JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Country Status (7)

Country Link
US (5) US10030048B2 (https=)
EP (1) EP3197474B1 (https=)
JP (3) JP6851965B2 (https=)
CN (2) CN114432423A (https=)
AU (2) AU2015320341B2 (https=)
CA (1) CA2999711A1 (https=)
WO (1) WO2016049580A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432423A (zh) 2014-09-26 2022-05-06 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFkB活性的抑制剂
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
CA3191058A1 (en) * 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3039802B2 (ja) * 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
WO1991002537A1 (en) 1989-08-14 1991-03-07 The Regents Of The University Of California Synthetic peptides that enhance cell binding
AU1404395A (en) * 1993-12-13 1995-07-03 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3987120B2 (ja) * 1996-09-05 2007-10-03 リサーチ ディベロップメント ファンデーション カフェイン酸フェネチル・エステル（ＣＡＰＥ）、ＣＡＰＥの誘導体、カプサイシン（８―メチル―Ｎ―バニリル―６―ノネンアミド）及び樹脂分泌毒素による核転写ファクターＮＦ―κＢの抑制
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
DK1678209T3 (da) * 2003-10-07 2011-06-27 Yeda Res & Dev Antistoffer mod nik, deres frembringelse samt anvendelse
EP1869206A4 (en) * 2005-03-02 2011-08-10 Einstein Coll Med ENZYME SENSORS WITH ENVIRONMENTAL SENSITIVE OR FLUORESCENT LABELS AND APPLICATIONS THEREOF
US20070009568A1 (en) 2005-06-03 2007-01-11 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
EP2150273A4 (en) 2007-04-27 2010-11-17 Univ Toledo MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
JP5702371B2 (ja) * 2009-05-27 2015-04-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
WO2011087768A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
CN114432423A (zh) 2014-09-26 2022-05-06 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFkB活性的抑制剂
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
CA3191058A1 (en) 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Similar Documents

Publication Publication Date Title
JP2021091728A5 (https=)
AU650020B2 (en) Method for increasing blood-brain barrier permeability
US9340583B2 (en) VIP fragments and methods of use
US5470828A (en) Peptide analogs of insulin-like growth factor II
JP2000507617A (ja) ヘプタペプチドオキシトシン類似体
JP2023010979A5 (https=)
WO2022002186A1 (zh) 用于修复黏膜损伤或皮肤创伤的多肽及其应用
WO1990009162A2 (en) Anaphylatoxin-receptor ligands
CA2140907A1 (en) Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
IE914398A1 (en) Hexa- and heptapeptide anaphylatoxin-receptor ligands
US5387671A (en) Hexa- and heptapeptide anaphylatoxin-receptor ligands
AU638468B2 (en) Hemoregulatory peptides
DE69430295T2 (de) Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe
EP0526192B1 (en) Hexapeptide
HU199879B (en) Process for producing hexapeptides and pharmaceutical compositions comprising same as active ingredient
Deunas et al. Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme
AU2016255690B2 (en) Pharmaceutical compound
EP0542934B1 (en) Use of somatostatin analogues for treating melanomas
JP2018500274A5 (https=)
JP2021531246A5 (https=)
CN114364691B (zh) 作为纤维化基质积累的抑制剂的肽
US20200095303A1 (en) Pharmaceutical compound
JPH03502336A (ja) 魚のｃｒｆ
US5776900A (en) Hemoregulatory peptides
JPWO2020012478A5 (https=)